While drug makers have discretion over how to price their products, they are clearly responsive to the incentives they face. In a new paper, we study whether the incentives from one major public program—Medicare Part D—have contributed to higher list prices of branded drugs over time.
How Medicare Shapes Drug Prices
Comment
Show comments
Hide Comments
